Outlook Therapeutics (OTLK) Assets Average (2016 - 2026)

Outlook Therapeutics (OTLK) has 11 years of Assets Average data on file, last reported at $20.1 million in Q1 2026.

• Assets Average for Q1 2026 came in at $20.1 million, up 11.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.1 million (up 11.22% YoY), and the FY2025 annual result was $23.7 million, down 22.44% from the prior year.
• Assets Average climbed to $20.1 million in Q1 2026 per OTLK's latest filing, from $18.4 million in the prior quarter.
• Over five years, Assets Average peaked at $73.2 million in Q1 2022 and troughed at $18.0 million in Q1 2025.
• A 5-year average of $37.1 million and a median of $38.0 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average soared 153.97% in 2022, then tumbled 60.92% in 2025.
• A 5-year view of Assets Average shows it stood at $45.6 million in 2022, then plunged by 40.82% to $27.0 million in 2023, then declined by 15.11% to $22.9 million in 2024, then declined by 19.65% to $18.4 million in 2025, then climbed by 8.98% to $20.1 million in 2026.
• Business Quant data shows OTLK's Assets Average at $20.1 million in Q1 2026, $18.4 million in Q4 2025, and $20.5 million in Q3 2025.